2 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
The primary objective is to investigate the efficacy of a single intradiscal injection of STA363 into one or two IVDs as compared to placebo by the following primary efficacy endpoint:* Change from baseline at Month 6 in mean pain intensity measured…